Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Clinical Trial Information

A study to assess the efficacy and safety of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)

Study Details

Main inclusion criteria:

  1. Clinical diagnosis of PN for at least 6 months with Pruriginous nodular lesions on upper limbs, trunk, and/or lower limbs. At least 20 nodules on the entire body with a bilateral distribution with IGA score ≥ 3.
     
  2. Severe pruritus defined as ≥ 7 on the PP NRS.
     
  3. Lack of any other primary pruritic skin condition.

Primary Sponsor:

Galderma

Prinicipal Investigator:

Dr. Jonathan Silverberg

Contact Phone:

(202) 667-6160
A study to assess the efficacy and safety of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) ntolstoy@mfa.gwu.edu

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)